Health Condition 1: A150- Tuberculosis of lung Health Condition 2: A150- Tuberculosis of lung
Conditions
Interventions
Intervention1: one group will receive 3 months daily Isoniazid and Rifampicin tablets (H-dose @ 10 mg/kg/day1, max 300 mg
R- 15 mg/kg/day1, max 600 mg)
: (isoniazid-dose @ 10 mg/kg/day1, max 300 mg
Rifampicin- 15 mg/kg/day1, max 600 mg)
Control Intervention1: One group will receive Isoniazid monotherapy for 6 months daily- dose @ 10 mg/kg/day1, max 300 mg.: rifampicin - dose @ 10 mg/kg/day1, ma
Sponsors
DR SHIVANGI SINHAL
Eligibility
Inclusion criteria
Inclusion criteria: children (6-14years)with LTBI living with sputum smear positive adult TB patients undergoing DOTS
Exclusion criteria
Exclusion criteria: children in contact with adults having multidrug resistant TB (MDR-TB) or Extensively drug resistanT TB(XDR-TB).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of children with LTBI developing Tuberculosis at 9 months after receiving treatment with 3 months HR v/s 6 months INH will be calculated and compared. Timepoint: 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| both groups will be compared in terms of adverse effectsTimepoint: 2 years | — |
Countries
India
Contacts
Public ContactDR GEETIKA SRIVASTAVA
ERAS LUCKNOW MEDICAL COLLEGE
Outcome results
None listed